Eli Lilly and Company ($LLY) Stock Forecast: Up 15.4% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company known for its innovative drugs and treatments. Today, the stock had a strong bullish movement in the market.

Why is Eli Lilly and Company going up?

LLY stock is up 15.4% on Apr 17, 2025 17:35

• Eli Lilly's stock soared after its oral GLP-1 drug, Orforglipron, successfully met Phase 3 goals in a diabetes trial, showing promising results in reducing A1C levels and weight in patients.
• Analysts are optimistic about the global potential of Orforglipron, with sales forecasts exceeding consensus estimates, leading to increased investor confidence in Eli Lilly's future prospects.
• The launch of Eli Lilly's weight-loss drug, Mounjaro, in India has triggered a craze in the market, showcasing the company's ability to innovate and capture consumer interest in new products.
• The positive news surrounding Eli Lilly's drug developments contrasts with Pfizer's decision to halt obesity pill development due to safety concerns, further highlighting the importance of successful clinical trials in the pharmaceutical industry.

LLY Price Chart

LLY Technical Analysis

LLY News

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential - Eli Lilly ( NYSE:LLY )

Orforglipron lowered A1C by 1.3%-1.6% from a baseline of 8.0% at 40 weeks. BofA forecasts 2030 orforglipron sales at $10 billion vs. $9 billion consensus estimate. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...

https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars - Eli Lilly ( NYSE:LLY )

Orforglipron cut A1C by 1.2-1.5% and reduced weight up to 15.8 lbs in adults with type 2 diabetes. Over 65% of high-dose patients reached an A1C of 6.5% or less after 40 weeks of treatment. Feel unsure about the market's next move?

https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher

Eli Lilly ( LLY ) Gains As Market Dips: What You Should Know

In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.

https://www.zacks.com/stock/news/2449437/eli-lilly-lly-gains-as-market-dips-what-you-should-know

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch - Eli Lilly ( NYSE:LLY )

Elevate Now received 200+ calls in one week about Mounjaro after its launch. Mounjaro is priced at ₹4,375 ( $50.86 ) for 5 mg and ₹3,500 for 2.5 mg in India. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.

https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch

Pfizer Halts Obesity Pill Development Amid Safety Concerns

PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.

https://www.zacks.com/stock/news/2449400/pfizer-halts-obesity-pill-development-amid-safety-concerns

Trending Today

Pepe ($PEPE) Crypto Forecast: Down 6.7% Today

Decentraland ($MANA) Crypto Forecast: Down 5.5% Today

Gala ($GALA) Crypto Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.2% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.5% Today

Memecoin ($MEME) Crypto Forecast: Down 5.2% Today

dogwifhat ($WIF) Crypto Forecast: Down 8.2% Today

Toncoin ($TON) Crypto Forecast: Up 5.1% Today

Aave ($AAVE) Crypto Forecast: Up 5.5% Today

Bonk ($BONK) Crypto Forecast: Up 16.6% Today

Eli Lilly and Company Price History

17.03.2025 - LLY Stock was up 15.4%

• Eli Lilly's stock soared after its oral GLP-1 drug, Orforglipron, successfully met Phase 3 goals in a diabetes trial, showing promising results in reducing A1C levels and weight in patients.
• Analysts are optimistic about the global potential of Orforglipron, with sales forecasts exceeding consensus estimates, leading to increased investor confidence in Eli Lilly's future prospects.
• The launch of Eli Lilly's weight-loss drug, Mounjaro, in India has triggered a craze in the market, showcasing the company's ability to innovate and capture consumer interest in new products.
• The positive news surrounding Eli Lilly's drug developments contrasts with Pfizer's decision to halt obesity pill development due to safety concerns, further highlighting the importance of successful clinical trials in the pharmaceutical industry.

17.03.2025 - LLY Stock was up 11.4%

• Eli Lilly's stock saw a significant rise following positive results from its oral GLP-1 drug, Orforglipron, in a Phase 3 diabetes trial, demonstrating effectiveness in reducing A1C levels and weight for those with type 2 diabetes.
• The introduction of Eli Lilly's weight-loss medication, Mounjaro, into the Indian market sparked enthusiasm among investors, generating increased interest and positive outlook for the company.
• Speculations suggest that Pfizer's decision to halt an obesity drug development program on safety grounds may have contributed to further enhancing investor trust in Eli Lilly's innovative and secure drug portfolio, propelling its stock price upwards.
• In conclusion, Eli Lilly's recent accomplishments in drug trials and strategic product releases have solidified its position as a key player in the pharmaceutical sector. This has attracted investors and fueled the positive momentum in its stock performance.

20.11.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock rose notably following the endorsement from the European Medicines Agency (EMA) panel for expanded use of Omvoh in treating Crohn's Disease, underscoring the company's dedication to developing effective treatments.
• Despite another company's weight loss drug not meeting expectations, Eli Lilly's positive updates overshadowed any potential negativity in the pharmaceutical sector.
• The bearish options trends in Eli Lilly's stock may have been counterbalanced by the favorable endorsement from the CHMP, boosting investor confidence and fueling the upward trend.
• With speculation around the next trillion-dollar company, Eli Lilly's progress in healthcare solutions positions it well for potential future growth and market valuation.

04.03.2025 - LLY Stock was down 6.8%

• Eli Lilly stock saw a notable decline despite a recent license agreement with Sangamo Therapeutics expected to bring in substantial revenue.
• Uncertainty over proposed tariffs on pharmaceutical imports by the current administration has had a negative impact on Eli Lilly, Pfizer (PFE), and Merck (MRK) stocks.
• Although there was smart money interest and support from financial giants, Eli Lilly's stock faced a significant decline, likely influenced by broader market conditions and tariff-related concerns outweighing positive developments.

26.10.2024 - LLY Stock was up 5.4%

• The bullish movement in Eli Lilly's stock may be linked to the Biden-Harris Administration's proposed rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, potentially boosting investor confidence in the company's sales and revenue prospects.
• Insider purchases by figures like Ralph Alvarez and J. Erik Fyrwald could have also positively influenced market sentiments around Eli Lilly, with insider buying typically regarded as a signal of confidence in the company's future.
• Despite recent challenges and a decline in stock price over the past month, these insider purchases and favorable regulatory updates appear to have eclipsed previous concerns, resulting in the significant bullish movement in Eli Lilly's stock today.

14.00.2025 - LLY Stock was down 5.1%

• Despite the overall market decline, Eli Lilly's stock price increased by +1.07%.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion could have positively influenced investor sentiment towards Eli Lilly.
• The anticipation of weight loss resolutions in the new year may have contributed to the optimistic outlook for Eli Lilly's stock.
• Investors holding onto Eli Lilly stock despite a recent 14% fall in the past 3 months indicates confidence in the company's future growth prospects.

09.03.2025 - LLY Stock was down 6.9%

• The partnership between Sangamo Therapeutics and Eli Lilly might have caused investors to shift their focus towards Sangamo, leading to a sell-off in LLY.
• Investors may see Sangamo's potential for significant earnings through the license agreement as a more attractive opportunity compared to LLY's current market position.
• The competition between LLY and NVO in the weight-loss drug sector could also be influencing investor sentiment, with some choosing to reallocate their investments from LLY to NVO.

20.10.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock surged after announcing positive Phase 2 results for muvalaplin, an investigational drug that showed promising efficacy in reducing sticky cholesterol levels by almost 86%.
• Investor sentiment was further boosted by a notable endorsement on a financial media show, where the recommendation to buy Eli Lilly stock was made, citing its potential despite being previously unpopular.
• The detailed Phase 3 data release showing impressive results from a study of tirzepatide also contributed to the positive market response, indicating strong growth prospects for Eli Lilly in the pharmaceutical sector.

07.02.2025 - LLY Stock was down 5.2%

• The partnership between Teladoc Health and Eli Lilly's LillyDirect to expand access to Zepbound for weight loss possibly sparked concerns among investors about the competitive landscape in the weight management sector, influencing a bearish sentiment towards Eli Lilly.
• The bullish options activity on Eli Lilly might reflect conflicting sentiments among investors, with some anticipating positive outcomes while others exercise caution, contributing to the stock's downward trend.
• Novo Nordisk's efforts to enhance Wegovy access through reduced pricing and home delivery could have exerted pressure on Eli Lilly's stock as investors reassess the competitive pricing and accessibility of weight management treatments in the market.
• Despite Eli Lilly's historical superior performance over the last two decades, recent developments and competitive pressures in the weight management sector may have cast a shadow on its long-term success, triggering a bearish market movement today.

10.03.2025 - LLY Stock was down 5.4%

• Wealthy investors have taken a pessimistic position on Eli Lilly, as evidenced by the latest options trends, potentially impacting the stock's downturn.
• The announcement of a 90-day pause on tariffs by President Trump benefited pharmaceutical stocks, including Eli Lilly, but the initial effects of the anticipated import tariff had already negatively influenced the stock price.
• The collaboration update with Sangamo Therapeutics could have initially boosted investor confidence. However, various market conditions seemed to overshadow this positive development, contributing to Eli Lilly's stock decline.
• In summary, the combination of bearish options trends, tariff uncertainties, and general market instability likely played a role in the downward trend of Eli Lilly's stock today.

06.01.2025 - LLY Stock was up 3.1%

• Q4 earnings report for Eli Lilly exceeded expectations, showing a 45% YoY revenue increase driven by strong demand for Mounjaro and Zepbound.
• The company's 2025 sales forecast of $58B-$61B, with a 32% growth midpoint, fueled investor optimism and contributed to the bullish momentum in the stock.
• Analysts are bullish on LLY, with price targets averaging $1066, indicating a 27% upside potential, supported by the anticipated success of new medicines and expanded market launches.
• The positive sentiment surrounding Eli Lilly's earnings and future prospects likely led to the strong bullish movement in the stock today.

14.00.2025 - LLY Stock was down 6.3%

• Eli Lilly cut its Q4 revenue guidance, expecting around $5.5 billion in sales from weight loss/diabetes drugs, leading to a bearish sentiment among investors.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion might have raised concerns about the company's future expenses and profitability.
• The comparison with Novo Nordisk as the best weight loss stock for 2025 could have shifted investor focus and triggered profit-taking in Eli Lilly shares.
• Despite the recent decline in stock price, analysts suggest holding onto Eli Lilly due to its robust growth prospects, indicating a potential rebound in the future.